The nation of Zimbabwe has rejected a substantial US healthcare agreement valued at 367 million US dollars (£272m) over five years due to Washington's demand for confidential information.
The decision was revealed following a government memo dated December was leaked, indicating that President Emmerson Mnangagwa deemed the arrangement was "skewed".
A government representative has since explained that the United States was demanding access to biological samples for research and profit but refused to share the resulting advantages from any future vaccines.
"We will now turn to the difficult and regrettable task of winding down our health aid in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the US had furnished over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has appealed for continued dialogue to secure a deal suitable to both sides so the nation's vital HIV treatment initiative can continue.
Wider Context
This rejection comes after a similar situation in Kenya, where a high court suspended a similar health funding agreement following concerns were raised about the security of citizens' health data.
After resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
USAID had overseen assistance for the American government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing government-to-government deals to enhance transparency and responsibility.
According to statements, 16 African countries have to date signed similar health pacts, constituting more than $18.3bn of fresh investment.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation could have provided extraordinary benefits for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment via US-supported initiatives," Tremont added.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Our nation was requested to share its biological resources and data over an extended period, without any equivalent guarantee of benefiting from any medical innovations – like new medicines or tests – that might be developed from that provided information," his statement read.
"Put simply, our country would provide the raw materials for medical research without any assurance that the end products would be accessible to our population should a new pandemic emerge."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one health agreements were undermining systems previously established through the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to deal with potential global health emergencies.
"This system is designed to guarantee that when a country provides its information, the resulting advantages – including medicines and cures – are shared equitably, not commercialised solely by those with the resources to develop them."
These objections over the US deal "must not be interpreted as hostility towards the US," Mangwana stressed.
"We encourage further dialogue with our American counterparts on how future co-operation could be arranged in a manner that respects the sovereignty and dignity of each country."
Health Experts Response
A leading public health body said it acknowledged the government's concerns, but suggested that negotiations must proceed since much of the nation's Aids initiatives relied on foreign aid.
"In cases where specific concerns exist, such as those relating to data governance or implementation frameworks, these can frequently be resolved through detailed discussion and negotiated safeguards," it commented.
This impasse underscores the continuing tensions between receiving much-needed international aid and protecting local interests in an increasingly data-driven world.